Clinical trials: Ductal Carcinoma
Breast Cancer, Carcinoma
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
PRINCIPAL INVESTIGATORS Rakesh Patel, MD- Radiation Oncologist Peter Beitsch, MD- Breast Surgeon REGISTRY DESIGN Multicenter, non-randomized, post market registry of intracavitary accelerated partial breast irradiation in…
- Conditions
- Breast Cancer, Carcinoma, Lumpectomy, Ductal Carcinoma in Situ
- Trial name
- EXIBT (NCT00742222)
- Testing
- Electronic Brachytherapy, Intracavitary accelerated partial breast irradiation
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- Xoft, Inc.
Tubular Breast Cancer, Mucinous Breast Cancer
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
The investigators hypothesize that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.
- Conditions
- Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
- Trial name
- SHPD002 (NCT02221999)
- Testing
- Paclitaxel, Cisplatin, Gonadotropin-releasing hormone agonist
- Where
- 12 sites in China
- Volunteers
- 250 people
- Sponsor
- RenJi Hospital
Carcinoma, Ductal, Breast, Menopausal
Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy
The primary objective of this monocentric and feasibility study is to review the efficacy of cryotherapy in the treatment of unifocal mammary carcinomas in post-menopausal patients, with lumpectomy indication.
- Trial name
- CRYOSE01 (NCT02576106)
- Testing
- Cryoablation
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Centre Leon Berard
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
Continuous Monitoring on the General Ward
Rationale: Monitoring patients' vital signs is done to detect clinical deterioration. For this, the MEWS, a scoring list comprising seven vital signs measured by nursing staff, is used.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Arthritis, Hypertension
- Trial name
- NCT02933307
- Testing
- HealthPatch, ViSi Mobile
- Volunteers
- 90 people
- Sponsor
- Radboud University Medical Center
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve…
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05178498
- Testing
- Follow-Up, Physical Examination, Questionnaire Administration
- Where
- United States
- Volunteers
- 960 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Thyroid Carcinoma, Thyroid Cancer
European Multicenter Study on Surgical Management of Advanced Thyroid Cancer
The main aim of the study is to evaluate peri-operative surgical characteristics, operation extent, postoperative morbidity, and outcomes in patients undergoing surgery for advanced thyroid cancer in different European centers…
- Conditions
- Thyroid Carcinoma, Thyroid Cancer, Thyroid Neoplasms, Thyroid Cancer, Papillary
- Trial name
- ATCEU (NCT05796960)
- Testing
- Thyroidectomy with or without lymphadenectomy or multivisceral resection
- Where
- Italy
- Volunteers
- 3,917 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Early Breast Cancer, Ductal Breast Carcinoma In Situ
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
- Trial name
- HFCBB (NCT06984250)
- Testing
- Hypofractionated Radiation Therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 315 people
- Sponsor
- National Taiwan University Hospital
Carcinoma, Pancreatic Ductal
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
The purpose of the study is to evaluate a new treatment strategy for advanced pancreatic cancer disease by combining the new investigational medicinal product Atu027 with the standard chemotherapeutic gemcitabine.
- Trial name
- Atu027-I-02 (NCT01808638)
- Testing
- Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1, Atu027 & gemcitabine in treatment arm 2
- Where
- 9 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Silence Therapeutics GmbH
Carcinoma, Invasive Ductal, Breast
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
It is a phase III trial to explore the efficacy and safety of vinorelbine plus capecitabine (NX) and docetaxel plus capecitabine (TX) as first line treatment followed by capecitabine alone till Progressive Disease(PD).
- Trial name
- NCT01126138
- Testing
- Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine, Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer Metastatic, Breast Carcinoma
Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer
Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and in symptomatic cases, up to…
- Trial name
- NCT07003009
- Testing
- Malign Lymph Node Washout, Benign Lymph Node Washout
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul Training and Research Hospital
Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma
"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
The purpose of this study is to evaluate a novel neoadjuvant regimen for invasive breast carcinoma by using the MD Anderson residual cancer burden score.To prospectively evaluate the utility of the PET scan to guide the…
- Conditions
- Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma
- Trial name
- NACprotocol (NCT01641406)
- Testing
- Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
- Where
- Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Auxilio Mutuo Cancer Center
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
This pilot clinical trial studies new ways to monitor the impact of hypofractionated image guided radiation therapy in treating patients with stage IV breast cancer. Radiation therapy uses high energy x rays to kill tumor cells.
- Conditions
- Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma
- Trial name
- NCT01706432
- Testing
- hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Chicago
Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
- Conditions
- Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer, Metastatic Anaplastic Thyroid Cancer, Metastatic Medullary Thyroid Cancer
- Trial name
- NCT00654238
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Pennsylvania
Metastatic Pancreatic Cancer
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) [PAG] to NAB and GEM [AG] in participants with Stage IV previously untreated pancreatic ductal…
- Trial name
- NCT01839487
- Testing
- PEGPH20, Nab-paclitaxel, Gemcitabine
- Where
- 51 sites in United States
- Volunteers
- 279 people
- Sponsor
- Halozyme Therapeutics
Early-stage Invasive Lobular Breast Carcinoma
AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast Carcinoma
Invasive lobular breast carcinoma (ILC), the second most common breast cancer type, represents approximately 15% of all breast cancer cases.
- Trial name
- NCT07842055
- Where
- Greece
- Volunteers
- 3,648 people
- Sponsor
- Hellenic Cooperative Oncology Group
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
This phase II trial studies how well carboplatin and paclitaxel with or without viral therapy works in treating patients with pancreatic cancer that has come back or has spread to other places in the body.
- Conditions
- Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
- Trial name
- NCT01280058
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Radiation Therapy in Treating Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00301041
- Testing
- laboratory biomarker analysis, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Epithelial Ovarian Cancer, Triple Negative Breast Cancer
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Study LCB-1801-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of NI-1801 in patients with advanced, metastatic, or recurrent solid malignancies expressing mesothelin…
- Conditions
- Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, Pancreatic Adenocarcinoma (ductal Adenocarcinoma)
- Trial name
- NCT05403554
- Testing
- Biological NI-1801, NI-1801 in combination with anti-PD1 (Pembrolizumab), NI-1801 in combination with paclitaxel
- Where
- 7 sites in France, Italy
- Volunteers
- 70 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Mastectomy, Breast Neoplasm Malignant Primary
Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study
Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging.
- Trial name
- NCT06505577
- Testing
- No additional intervention
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Incheon St.Mary's Hospital